Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
744 participants
INTERVENTIONAL
2016-11-30
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lifestyle Modification Intervention in Pre-diabetic Subjects
NCT03211182
Qingdao Diabetes Prevention Project
NCT01053195
Diabetes Prevention Program Outcomes Study
NCT00038727
Lifestyle Intervention in Individuals With Low or High Genetic Risk for Type 2 Diabetes
NCT02709057
A Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes
NCT07262788
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional Management
A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
No interventions assigned to this group
Life style modification
Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit).
* Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day)
* Diet remedies: Train Calorie intake, nutrient intake and Monitoring.
Exercise and Diet remedies
Metformin
After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
Metformin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise and Diet remedies
Metformin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI≥23 kg/m2
3. '75g Oral glucose tolerance 2 hours after the test Blood glucose140\~199mg/dL' or 'Fasting Blood Sugar 110\~125 mg/dL' or 'HbA1c 5.7%\~6.4%'
Exclusion Criteria
2. Type 2 Diabetes Mellitus
* Who diagnosed with Diabetes Mellitus except for maternity period.
* Who have had drugs for Diabetes Mellitus(hypoglycemic agent or insulin) except for maternity period.
* Fasting Glucose≥ 126 mg/dL
* 75g Oral glucose tolerance 2 hours after the Blood glucose ≥ 200 mg/dL
* HbA1c ≥ 6.5%
3. Who life expectancy is short.
* Cardiac history
* History of severe cardiovascular disease within the last 6 months (cerebral hemorrhage, stroke, myocardial infarction, angina pectoris, heart failure, etc.)
* Systolic blood pressure \>180 mmHg or Diastolic blood pressure \>105 mmHg
* aortic stenosis
* Left bundle branch block or Third degree AV block
* Who had been diagnosed and treated for malignant tumors including leukemia and lymphoma within the last 5 years
* Abnormal renal function (Creatinine ≥ 1.4 mg/dL (male) or ≥ 1.3 mg/dL (female) or Urine Protein ≥ 2 +)
* Anemia(Hematocrit \<36%((male) or\>\<33%(female)) ⑤ Cirrhosis or chronic active hepatitis (AST/ALT\>３UNL)
* Acute gastrointestinal disease (pancreatitis, infectious intestinal disease)
* Who is scheduled major surgery within the last 3 to 6 months or just after the surgery.
* Chronic infection (HIV, active tuberculosis, etc.)
* Pulmonary patients who rely on oxygen or daily bronchodilators
4. Who is judged to be able to influence the clinical trial by investigator.
* Who can not communicate
* Those with psychiatric or cognitive impairment that may affect the compliance of the clinical trial
* Those who do not agree to the treatment group allocation by random assignment
* Those who participate in other studies that may interfere with the clinical trial
* Those who lost weight by more than 10% during the past 6 months, excluding weight loss after giving birth
* Those who can not have normal walking or exercise
* Women who are pregnant
* Those who are currently pregnant or who are within the last 3 months after giving birth
* Those planning pregnancy during the clinical trial period
* Those who have a history of drug and alcohol abuse (acute, chronic) within the last 2 years
* Those who are not appropriate or unreliable for clinical trials at the discretion of the tester
5. Who taking medication or medical condition that may affect the diagnosis of diabetes
* Thiazide diuretics
* Systemic beta blockers
* Taking Niacin for the treatment of neutropenic depression
* Possibility of taking or injecting a systemic steroid preparation
* Taking a serotonin reuptake inhibitor (SSRI) for weight loss purpose.
* Taking medicine for weight loss
* Hormone status is not appropriate during thyroid hormone replacement therapy (TSH abnormal range) (If thyroid hormone therapy is stable for more than 3 months and TSH is normal, the patient can participate in)
* Others with other endocrine diseases (eg Cushing's syndrome, acromegaly)
* During treatment, fasting plasma triglyceride\> 600 mg / dL
31 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Evidence-Based Healthcare Collaborating Agency
OTHER_GOV
Kyungpook National University Hospital
OTHER
Korea University Guro Hospital
OTHER
Pusan National University Hospital
OTHER
Samsung Medical Center
OTHER
Seoul National University Hospital
OTHER
Asan Medical Center
OTHER
Ajou University School of Medicine
OTHER
Severance Hospital
OTHER
Chonbuk National University Hospital
OTHER
Jeong-taek Woo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeong-taek Woo
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyunghee University Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rhee SY, Chon S, Ahn KJ, Woo JT; Korean Diabetes Prevention Study Investigators. Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study. Diabetes Metab J. 2019 Feb;43(1):49-58. doi: 10.4093/dmj.2018.0033. Epub 2018 Nov 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KDPS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.